OR6C7P

Across TCGA pan-cancer cohorts, OR6C7P RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated OR6C7P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR6C7P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR6C7P expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, STAD, and KIRC are the cancer types where OR6C7P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.376	0.788	<.001	63	view →
STAD	DFS	Tertile	All	0.429	0.738	.002	45	view →
KIRC	DFS	Tertile	II,III,IV	0.141	0.508	.013	36	view →
THYM	DFS	Tertile	II,III,IV	0.172	0.747	.005	36	view →
LUSC	OS	Tertile	III,IV	0.079	0.691	<.001	36	view →
MESO	DFS	Tertile	All	0.099	0.392	.030	27	view →
LUAD	DFS	Tertile	II,III,IV	0.518	0.651	<.001	24	view →
COAD	OS	Tertile	III,IV	0.163	0.791	.004	18	view →
SKCM	DFS	Tertile	All	0.956	0.715	.019	18	view →
SARC	OS	Tertile	All	0.511	0.860	.044	9	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

OR6C7P–LIHC (OS)

Open the LIHC breakdown →